Skip to content
The Policy VaultThe Policy Vault

Rozlytrek (entrectinib capsules and oral pellets – Genentech) — Cigna

Solid Tumors with NTRK gene fusion

Initial criteria

  • Patient age ≥ 1 month
  • Tumor is positive for neurotrophic receptor tyrosine kinase (NTRK) gene fusion
  • EITHER tumor is metastatic OR surgical resection of the tumor will likely result in severe morbidity

Approval duration

1 year